Although the RFS of none of the molecular subtypes had an effect due to overall low expression of KIBRA, we identified that the luminal breast cancer patients, luminal A and B together, had a RFS disadvantage due to the overall low expression of KIBRA. The gene discussed is WWC1; the disease is breast carcinoma.